Aurora Cannabis accelerates global medical cannabis leadership with proactive acquisition of Safari Flower, expanding EU GMP capabilities to serve growing high-margin international markets.

EDMONTON, AB, April 15, 2026. /PRNewswire/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company based in Canada, is pleased to announce that it has acquired Safari Flower, an EU GMP certified cannabis developer and manufacturer. The aggregate consideration is valued at $26.5 million, subject to customary adjustments and including a $2 million cash payment contingent on the satisfaction of certain conditions (the “Deal”).

“The acquisition of Safari Flower is an important milestone for Aurora as we continue to make targeted investments in expanding our EU GMP capabilities to support the rapidly growing international medical cannabis market. The expanded supply chain will enable us to capture greater international market share while delivering superior quality and value to our most valued patients around the world,” said Miguel Martin, Aurora’s Executive Chairman and Chief Executive Officer.

Strategic rationale

• Safari Flower Company’s 59,000-square-foot, purpose-built EU GMP certified in-house processing and manufacturing facility in Ontario, Canada will provide the company with increased capacity that closely aligns with its existing cultivation and manufacturing facilities.
• The increased capacity will be used to supply EU GMP flower to Aurora’s key international markets, including Germany, Australia, Poland and the UK, and will support further market expansion.
• This transaction is expected to result in a positive adjusted EBITDA contribution in fiscal year 2027, with additional benefits in fiscal year 2028 and beyond as these assets are optimized in the Company’s supply chain.
• Aurora intends to leverage its plant science and operational expertise to drive operational efficiencies, improve crop yields and support high-margin commercialization in international markets.

Transaction details

Aurora, through a wholly-owned subsidiary, has indirectly purchased 100% of the shares of 9869247 Canada Limited (“Safari Flower Company”) for an aggregate consideration of $26.5 million, including a cash payment of $2 million subject to the satisfaction of certain conditions. As closing consideration, Aurora (i) issued to the selling stockholder 2,417,180 shares of common stock; and (ii) paid the selling stockholder $15 million in cash, subject to customary post-closing adjustments.

About Aurora

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves both medical and consumer markets in Canada, Europe, Australia and New Zealand with a strategic focus on high margin opportunities and a medical first approach. Aurora’s portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty’s® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products to open up the world to cannabis.

Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora common stock trades on the NASDAQ and TSX exchanges under the symbol “ACB”.

Original press release

Published by NCV Newswire

New Cannabis Ventures’ NCV Newswire aims to gather high-quality content and information about leading cannabis companies to help our readers filter through the noise and stay on top of the most important cannabis business news. The NCV Newswire is edited by an editor and is not automated in any way. Got a secret news tip? Get in touch.

You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.

friends,

Just before Christmas, this newsletter discussed how Vireo Growth is getting pretty big. At the end of January I profiled how Vireo Growth is expanding its business. This week’s newsletters include six articles we’ve run since April 2, and Vireo Growth is central to two of them. Vireo Growth is big and getting bigger, but few people seem to care.

I’m not writing this to tell readers to care. In fact, while I used to include the company on my Focus List at 420 Investor, I no longer do. Earlier this month I wrote an article for my subscribers about why I keep looking at things but not including stocks in my Focus List. Here is the summary.

I watch VREOF because it is now one of the largest MSOs by revenue, but it continues to fall short of joining the Global Hemp Stock Index due to its low trading volumes. Average daily trading volume over the past month was 251,000 shares, which is about $100,000 in daily trading value. This is well below peers. Perhaps more importantly, the current price of $0.45, which is down 26.6% year-to-date, is significantly lower than the price of $0.625 for the last large cap in 2024. Not only are the investors not winning, but VREOF hsa distributed a lot of shares to the sellers and they are also under water.

Maybe Vireo Growth shares will reward their owners, or maybe it will continue to do so. I think hemp stock investors and debt holders should be asking why no one is thinking of this yet. Scotts Miracle-Gro, which has been public since 1992 and has a market cap of $3.6 billion, picked up much of VREOF’s stock when it spun off Hawthorne. The 213 million shares are “at an implied price of $0.60” per share, although VREOF hasn’t traded at $0.60 since January. When the divestiture was announced in late January, Vireo Growth closed at $0.5553.

So a large MSO that has reshuffled its management, is now in multiple markets, and has executed its plan to get bigger with several acquisitions, is still not responding to the cannabis investment community. I wish them the best.

Sincerely,

Alan:

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we have published in the last 2 weeks.

Exclusives

The sale of hemp did not succeed until March

Michigan’s hemp sales are down again

Mergers and acquisitions

Aurora Cannabis acquires Cultivator for C$26.5 million

Greenhouse Brands and Vireo Growth Weak in California Cannabis Combination

Organigram Global Closes European Acquisition

Vireo Growth acquires Hawthorne Gardening Company

Follow Alan for real-time updates X.com:. Share and discover industry news with like-minded people on the largest group of cannabis investors and entrepreneurs LinkedIn:.

View: Public Hemp Company Revenue and Earnings Trackingwhich ranks the highest-earning hemp stocks.

Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.

Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El